Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
ACELYRIN, INC. - Common Stock
Factorial Energy Inc. - Class A Common Stock
Shoe Carnival, Inc. - Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Legend Biotech Corporation - American Depositary Shares
(NQ:
LEGN
)
16.10
-0.15 (-0.92%)
Delayed Quote
Updated: 4:00 PM EST, Nov 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Legend Biotech Corporation - American Depositary Shares
< Previous
1
2
3
4
5
Next >
Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
November 10, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
November 09, 2026
From
Gabelli Funds
Via
GlobeNewswire
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
November 04, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
October 27, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
October 15, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
October 01, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
September 25, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
September 15, 2026
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search process
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
September 10, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
September 01, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
August 11, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
July 28, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces CEO Transition
July 27, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026
Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Legend Biotech Corporation Announces Pricing of Public Offering
June 17, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Corporation Announces Proposed Public Offering
June 17, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 15, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 14, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
June 02, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
June 01, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Announces Presentations at ASCO 2026
May 21, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
May 12, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
May 04, 2026
Leading experts across cell therapy, oncology, and immunology will provide strategic input as Legend advances and expands beyond its current portfolio
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
April 28, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
March 10, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
February 24, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
January 21, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
December 06, 2025
From
Legend Biotech USA Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit